Intra-Cellular Therapies (ITCI) Financials

$131.87 0.00 (0.00%)

As of 04/2/2025

Annual Income Statements for Intra-Cellular Therapies

This table shows Intra-Cellular Therapies' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-105	-116	-98	-155	-148	-227	-284	-256	-140	-75
Consolidated Net Income / (Loss)	-105	-116	-98	-155	-148	-227	-284	-256	-140	-75
Net Income / (Loss) Continuing Operations	-105	-116	-98	-155	-148	-227	-284	-256	-140	-75
Total Pre-Tax Income	-105	-115	-99	-155	-148	-227	-284	-256	-139	-74
Total Operating Income	-106	-118	-103	-162	-154	-231	-286	-264	-159	-117
Total Gross Profit	0.09	0.33	0.25	0.00	0.06	21	76	230	431	624
Total Revenue	0.09	0.33	0.25	0.00	0.06	23	84	250	464	681
Operating Revenue	-	0.33	0.25	0.00	0.06	23	84	250	464	681
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	1.90	8.04	20	34	57
Operating Cost of Revenue	-	-	-	0.00	0.00	1.90	8.04	20	34	57
Total Operating Expenses	106	119	103	162	154	252	361	493	590	741
Selling, General & Admin Expense	18	25	24	30	65	186	273	359	410	504
Research & Development Expense	88	94	79	132	89	66	89	135	180	236
Total Other Income / (Expense), net	1.02	2.90	4.01	7.14	6.29	4.24	1.57	7.38	20	43
Interest & Investment Income	1.02	2.94	4.01	7.14	6.29	4.24	1.57	7.38	20	43
Income Tax Expense	0.00	1.07	-1.06	0.00	0.00	0.01	0.01	0.01	0.64	0.47
Basic Earnings per Share	($2.91)	($2.69)	($2.12)	($2.84)	($2.68)	($3.23)	($3.50)	($2.72)	($1.46)	($0.72)
Weighted Average Basic Shares Outstanding	36.07M	43.24M	46.18M	54.71M	55.19M	70.36M	81.25M	94.05M	95.88M	103.13M
Diluted Earnings per Share	($2.91)	($2.69)	($2.12)	($2.84)	($2.68)	($3.23)	($3.50)	($2.72)	($1.46)	($0.72)
Weighted Average Diluted Shares Outstanding	36.07M	43.24M	46.18M	54.71M	55.19M	70.36M	81.25M	94.05M	95.88M	103.13M
Weighted Average Basic & Diluted Shares Outstanding	36.07M	43.24M	46.18M	54.71M	55.19M	70.36M	81.25M	95.28M	96.81M	106.33M

This table shows Intra-Cellular Therapies' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-54	-44	-44	-43	-24	-29	-15	-16	-26	-17
Consolidated Net Income / (Loss)	-54	-44	-44	-43	-24	-29	-15	-16	-26	-17
Net Income / (Loss) Continuing Operations	-54	-44	-44	-43	-24	-29	-15	-16	-26	-17
Total Pre-Tax Income	-54	-44	-44	-43	-24	-28	-15	-16	-26	-17
Total Operating Income	-56	-47	-48	-47	-30	-34	-21	-28	-39	-29
Total Gross Profit	66	81	89	104	117	121	135	150	160	179
Total Revenue	72	88	95	111	126	132	145	161	175	199
Operating Revenue	72	88	95	111	126	132	145	161	175	199
Total Cost of Revenue	5.85	6.79	6.75	7.16	9.13	11	9.90	11	15	20
Operating Cost of Revenue	5.85	6.79	6.75	7.16	9.13	11	9.90	11	15	20
Total Operating Expenses	127	123	137	151	147	155	156	178	199	208
Selling, General & Admin Expense	88	95	99	101	105	105	113	122	132	138
Research & Development Expense	33	34	38	50	42	51	43	56	67	70
Total Other Income / (Expense), net	2.12	3.39	4.35	4.53	5.50	5.97	6.06	12	13	12
Interest & Investment Income	2.12	3.39	4.35	4.53	5.50	5.97	6.06	12	13	12
Income Tax Expense	0.00	-	0.01	0.14	0.04	0.45	0.36	0.06	0.37	-0.32
Basic Earnings per Share	($0.57)	($0.45)	($0.46)	($0.45)	($0.25)	($0.30)	($0.16)	($0.16)	($0.25)	($0.15)
Weighted Average Basic Shares Outstanding	94.52M	94.05M	95.13M	95.95M	96.14M	95.88M	96.88M	103.72M	105.77M	103.13M
Diluted Earnings per Share	($0.57)	($0.45)	($0.46)	($0.45)	($0.25)	($0.30)	($0.16)	($0.16)	($0.25)	($0.15)
Weighted Average Diluted Shares Outstanding	94.52M	94.05M	95.13M	95.95M	96.14M	95.88M	96.88M	103.72M	105.77M	103.13M
Weighted Average Basic & Diluted Shares Outstanding	94.71M	95.28M	95.93M	96.09M	96.24M	96.81M	105.57M	105.67M	106.02M	106.33M

This table details how cash moves in and out of Intra-Cellular Therapies' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	-14	1.48	-11	17	53	-46	32	57	-0.85	159
Net Cash From Operating Activities	-102	-91	-80	-118	-128	-230	-260	-270	-124	-73
Net Cash From Continuing Operating Activities	-102	-91	-80	-118	-128	-230	-260	-270	-124	-73
Net Income / (Loss) Continuing Operations	-105	-116	-98	-155	-148	-227	-284	-256	-140	-75
Consolidated Net Income / (Loss)	-105	-116	-98	-155	-148	-227	-284	-256	-140	-75
Depreciation Expense	0.14	0.20	0.21	0.37	0.48	0.53	0.53	0.66	0.53	0.51
Amortization Expense	0.71	0.54	0.43	-0.94	-1.13	-0.65	-4.08	0.45	-8.40	-9.03
Non-Cash Adjustments To Reconcile Net Income	11	15	15	18	22	24	34	44	52	64
Changes in Operating Assets and Liabilities, net	-9.41	9.49	1.81	20	-1.48	-27	-6.18	-59	-28	-54
Net Cash From Investing Activities	-362	92	-93	135	177	-480	280	-128	106	-335
Net Cash From Continuing Investing Activities	-362	92	-93	135	177	-480	280	-128	106	-335
Purchase of Property, Plant & Equipment	-0.86	-0.05	-0.72	-0.39	-0.70	-0.27	-0.33	-0.78	-0.27	-0.32
Purchase of Investments	-514	-396	-521	-271	-81	-756	-225	-759	-415	-740
Sale and/or Maturity of Investments	153	488	429	406	259	276	505	632	521	405
Net Cash From Financing Activities	450	0.48	162	0.69	3.24	664	12	455	18	568
Net Cash From Continuing Financing Activities	450	0.48	162	0.69	3.24	664	12	455	18	568
Issuance of Common Equity	450	0.00	162	0.00	0.00	653	0.00	434	0.00	543
Other Financing Activities, net	0.65	0.48	0.29	0.69	3.24	11	12	21	18	24
Cash Income Taxes Paid	0.00	1.00	0.00	0.00	0.00	0.00	0.01	0.01	0.16	1.82

This table details how cash moves in and out of Intra-Cellular Therapies' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	58	13	-73	67	-43	48	-7.95	553	-229	-157
Net Cash From Operating Activities	-53	-39	-60	-37	-25	-2.06	-34	0.54	-27	-13
Net Cash From Continuing Operating Activities	-53	-39	-60	-37	-25	-2.06	-34	0.54	-27	-13
Net Income / (Loss) Continuing Operations	-54	-44	-44	-43	-24	-29	-15	-16	-26	-17
Consolidated Net Income / (Loss)	-54	-44	-44	-43	-24	-29	-15	-16	-26	-17
Depreciation Expense	0.17	0.14	0.13	0.12	0.14	0.14	0.13	0.13	0.14	0.11
Amortization Expense	0.23	1.16	-1.74	-1.93	-2.19	-2.54	-2.34	-1.85	-1.85	-2.99
Non-Cash Adjustments To Reconcile Net Income	10	12	9.54	13	14	15	14	16	17	16
Changes in Operating Assets and Liabilities, net	-10	-8.23	-24	-5.37	-13	14	-31	2.32	-16	-9.52
Net Cash From Investing Activities	106	50	-16	95	-20	47	16	7.77	-209	-150
Net Cash From Continuing Investing Activities	106	50	-16	95	-20	47	16	7.77	-209	-150
Purchase of Property, Plant & Equipment	-0.12	0.03	-	-	-0.27	-0.00	-	-	-0.70	0.43
Purchase of Investments	-91	-116	-108	-66	-136	-104	-81	-89	-313	-258
Sale and/or Maturity of Investments	197	166	92	161	116	152	97	96	104	107
Net Cash From Financing Activities	5.65	2.19	3.64	8.59	2.58	3.00	9.99	545	6.73	5.61
Net Cash From Continuing Financing Activities	5.65	2.19	3.64	8.59	2.58	3.00	9.99	545	6.73	5.61
Other Financing Activities, net	5.65	2.19	3.64	8.59	2.58	3.00	9.99	2.09	6.73	5.61
Cash Income Taxes Paid	-	-	-	-	-0.01	0.16	-	-	-	0.46

This table presents Intra-Cellular Therapies' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	484	389	471	357	251	717	490	755	728	1,367
Total Current Assets	483	388	469	355	230	691	467	738	668	1,307
Cash & Equivalents	47	49	38	55	108	60	92	149	148	307
Restricted Cash	-	-	-	-	0.00	1.40	1.40	1.75	1.75	1.75
Short-Term Investments	428	335	427	293	116	597	320	443	350	694
Accounts Receivable	0.03	0.09	-	-	0.00	11	20	75	114	167
Inventories, net	-	-	-	-	0.00	7.06	7.95	24	12	26
Prepaid Expenses	8.03	4.01	4.88	7.91	6.31	14	25	45	42	112
Plant, Property, & Equipment, net	0.78	0.63	1.14	1.16	2.26	2.00	1.79	1.91	1.65	1.47
Total Noncurrent Assets	0.07	0.08	1.13	0.61	19	24	21	15	59	58
Other Noncurrent Operating Assets	0.07	0.08	0.08	0.08	18	24	21	15	59	58
Total Liabilities & Shareholders' Equity	484	389	471	357	251	717	490	755	728	1,367
Total Liabilities	7.86	13	17	39	56	60	72	99	137	218
Total Current Liabilities	6.26	11	14	36	36	37	53	83	124	206
Accounts Payable	1.63	3.75	6.17	14	7.43	5.50	8.69	10	11	26
Accrued Expenses	3.42	5.33	6.42	20	16	11	17	45	81	141
Current Employee Benefit Liabilities	1.21	1.45	1.61	2.29	9.47	15	21	23	27	35
Other Current Liabilities	-	-	-	0.00	3.19	5.54	6.73	4.57	3.61	4.23
Total Noncurrent Liabilities	1.60	2.87	2.84	3.19	20	24	19	15	13	13
Other Noncurrent Operating Liabilities	-	-	-	0.00	20	24	19	15	13	13
Total Equity & Noncontrolling Interests	476	376	454	318	195	657	418	656	591	1,148
Total Preferred & Common Equity	476	376	454	318	195	657	418	656	591	1,148
Total Common Equity	476	376	454	318	195	657	418	656	591	1,148
Common Stock	670	685	862	881	905	1,593	1,639	2,138	2,208	2,840
Retained Earnings	-193	-309	-407	-562	-710	-937	-1,221	-1,477	-1,617	-1,692
Accumulated Other Comprehensive Income / (Loss)	-0.59	-0.32	-0.80	-0.67	0.13	0.48	-0.36	-4.19	0.10	0.19

This table presents Intra-Cellular Therapies' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	782	722	714	718	747	1,321	1,324
Total Current Assets	760	706	698	702	691	1,264	1,272
Cash & Equivalents	135	76	142	99	140	693	464
Restricted Cash	1.75	1.75	1.75	1.75	1.75	1.75	1.75
Short-Term Investments	493	463	371	394	336	330	542
Accounts Receivable	62	82	96	103	131	146	146
Inventories, net	24	28	42	43	16	20	24
Prepaid Expenses	44	56	46	62	66	74	94
Plant, Property, & Equipment, net	2.08	1.78	1.66	1.79	1.52	1.45	2.01
Total Noncurrent Assets	20	14	14	13	55	55	51
Other Noncurrent Operating Assets	20	14	14	13	55	55	51
Total Liabilities & Shareholders' Equity	782	722	714	718	747	1,321	1,324
Total Liabilities	97	95	107	117	148	176	180
Total Current Liabilities	77	80	92	103	135	162	166
Accounts Payable	14	8.44	7.73	11	12	18	10
Accrued Expenses	35	51	59	63	103	118	122
Current Employee Benefit Liabilities	21	17	22	25	16	22	29
Other Current Liabilities	7.25	3.53	3.56	3.58	3.64	4.17	4.20
Total Noncurrent Liabilities	19	15	14	14	13	14	14
Other Noncurrent Operating Liabilities	19	15	14	14	13	14	14
Total Equity & Noncontrolling Interests	685	628	607	601	599	1,145	1,145
Total Preferred & Common Equity	685	628	607	601	599	1,145	1,145
Total Common Equity	685	628	607	601	599	1,145	1,145
Common Stock	2,124	2,152	2,174	2,191	2,232	2,794	2,818
Retained Earnings	-1,433	-1,522	-1,564	-1,589	-1,632	-1,649	-1,675
Accumulated Other Comprehensive Income / (Loss)	-5.50	-2.70	-2.27	-1.34	-0.43	-0.67	1.63

This table displays calculated financial ratios and metrics derived from Intra-Cellular Therapies' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-84.17%	261.96%	-25.66%	-100.00%	0.00%	37,537.14%	267.35%	198.69%	85.52%	46.62%
EBITDA Growth	-242.30%	-11.96%	13.04%	-59.34%	5.02%	-49.58%	-25.02%	9.24%	36.29%	25.12%
EBIT Growth	-241.48%	-11.76%	13.04%	-57.79%	5.09%	-50.14%	-23.55%	7.72%	39.54%	26.77%
NOPAT Growth	-241.48%	-11.76%	13.04%	-57.79%	5.09%	-50.14%	-23.55%	7.72%	39.54%	26.77%
Net Income Growth	-241.44%	-11.10%	16.02%	-58.66%	4.77%	-53.67%	-25.16%	9.81%	45.49%	46.54%
EPS Growth	-171.96%	7.56%	21.19%	-33.96%	5.63%	-20.52%	-8.36%	22.29%	46.32%	50.68%
Operating Cash Flow Growth	-348.46%	10.78%	11.80%	-46.81%	-8.31%	-79.77%	-12.81%	-4.10%	54.03%	41.08%
Free Cash Flow Firm Growth	-364.31%	13.14%	3.35%	-32.50%	-15.97%	-73.88%	-9.13%	-17.79%	41.97%	3.74%
Invested Capital Growth	111.47%	-924.69%	-15.07%	-201.35%	2.73%	93.15%	309.11%	1,401.44%	46.97%	58.77%
Revenue Q/Q Growth	-27.81%	25.52%	-27.41%	-100.00%	0.00%	118.95%	18.72%	33.06%	10.53%	10.94%
EBITDA Q/Q Growth	-15.39%	1.07%	-4.89%	-6.76%	0.67%	-9.36%	-9.44%	13.37%	5.43%	3.41%
EBIT Q/Q Growth	-15.34%	1.12%	-4.76%	-6.51%	0.55%	-9.24%	-9.45%	12.77%	7.71%	4.03%
NOPAT Q/Q Growth	-15.34%	1.12%	-4.76%	-6.51%	0.55%	-9.24%	-9.45%	12.77%	7.71%	4.03%
Net Income Q/Q Growth	-14.96%	1.15%	-2.87%	-7.29%	0.11%	-9.72%	-9.66%	14.00%	9.96%	13.54%
EPS Q/Q Growth	-5.05%	1.10%	3.64%	-7.17%	0.37%	-0.31%	-9.38%	18.07%	9.32%	17.24%
Operating Cash Flow Q/Q Growth	-39.29%	6.75%	4.35%	-3.84%	-4.83%	-16.86%	-1.94%	11.17%	23.02%	-17.72%
Free Cash Flow Firm Q/Q Growth	-46.98%	10.46%	4.24%	-3.97%	-6.27%	-16.04%	-0.68%	6.04%	18.03%	-17.17%
Invested Capital Q/Q Growth	111.74%	21.20%	-70.41%	-33.33%	-1.57%	85.75%	-48.50%	13.62%	-13.39%	6.69%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	0.00%	100.00%	91.69%	90.41%	91.83%	92.73%	91.63%
EBITDA Margin	-114,882.99%	-35,535.82%	-41,570.80%	0.00%	-255,170.22%	-1,014.11%	-345.14%	-104.88%	-36.02%	-18.39%
Operating Margin	-115,815.85%	-35,759.96%	-41,832.65%	0.00%	-254,090.46%	-1,013.58%	-340.90%	-105.32%	-34.32%	-17.14%
EBIT Margin	-115,815.85%	-35,759.96%	-41,832.65%	0.00%	-254,090.46%	-1,013.58%	-340.90%	-105.32%	-34.32%	-17.14%
Profit (Net Income) Margin	-114,698.50%	-35,205.79%	-39,771.64%	0.00%	-243,713.69%	-995.07%	-339.04%	-102.37%	-30.08%	-10.97%
Tax Burden Percent	100.00%	100.92%	98.93%	100.00%	100.00%	100.01%	100.00%	100.00%	100.46%	100.64%
Interest Burden Percent	99.03%	97.55%	96.10%	95.60%	95.92%	98.17%	99.45%	97.20%	87.24%	63.57%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-18,439.60%	-554.40%	-144.75%	-68.84%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-18,423.91%	-540.16%	-139.61%	-69.78%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	18,386.73%	506.68%	122.36%	60.26%
Return on Equity (ROE)	-35.12%	-27.34%	-23.56%	-40.18%	-57.62%	-53.30%	-52.87%	-47.72%	-22.39%	-8.58%
Cash Return on Invested Capital (CROIC)	-8,076.39%	0.00%	0.00%	0.00%	0.00%	0.00%	-4,958.54%	-729.42%	-182.79%	-114.26%
Operating Return on Assets (OROA)	-34.40%	-27.09%	-23.91%	0.00%	-50.63%	-47.75%	-47.33%	-42.36%	-21.49%	-11.14%
Return on Assets (ROA)	-34.07%	-26.67%	-22.73%	0.00%	-48.56%	-46.88%	-47.07%	-41.18%	-18.84%	-7.13%
Return on Common Equity (ROCE)	-35.12%	-27.34%	-23.56%	-40.18%	-57.62%	-53.30%	-52.87%	-47.72%	-22.39%	-8.58%
Return on Equity Simple (ROE_SIMPLE)	-22.00%	-31.01%	-21.52%	-48.83%	-75.75%	-34.56%	-67.99%	-39.06%	-23.62%	-6.50%
Net Operating Profit after Tax (NOPAT)	-74	-83	-72	-114	-108	-162	-200	-185	-112	-82
NOPAT Margin	-81,071.10%	-25,031.97%	-29,282.85%	0.00%	-177,863.32%	-709.51%	-238.63%	-73.72%	-24.03%	-12.00%
Net Nonoperating Expense Percent (NNEP)	-10.16%	-7.83%	-6.08%	-10.23%	-13.97%	-14.76%	-15.69%	-14.24%	-5.14%	0.94%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-28.13%	-18.86%	-7.11%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	8.31%	9.59%	8.17%	7.27%	8.37%
SG&A Expenses to Revenue	19,906.40%	7,486.52%	9,627.09%	0.00%	107,151.31%	816.92%	325.30%	143.33%	88.26%	74.10%
R&D to Revenue	96,009.45%	28,373.44%	32,305.56%	0.00%	147,039.15%	288.35%	106.02%	53.82%	38.79%	34.68%
Operating Expenses to Revenue	115,915.85%	35,859.96%	41,932.65%	0.00%	254,190.46%	1,105.27%	431.32%	197.15%	127.06%	108.78%
Earnings before Interest and Taxes (EBIT)	-106	-118	-103	-162	-154	-231	-286	-264	-159	-117
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-105	-118	-102	-163	-155	-231	-289	-263	-167	-125
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.86	1.74	1.74	1.96	9.72	3.88	10.20	7.64	11.65	7.71
Price to Tangible Book Value (P/TBV)	4.86	1.74	1.74	1.96	9.72	3.88	10.20	7.64	11.65	7.71
Price to Revenue (P/Rev)	25,329.27	1,974.34	3,214.67	0.00	31,280.51	111.74	50.88	20.02	14.84	13.01
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1,763.87	0.00	0.00	0.00	0.00	0.00	926.16	70.79	69.69	53.91
Enterprise Value to Revenue (EV/Rev)	20,128.09	812.87	1,325.89	0.00	27,584.77	82.85	45.94	17.65	13.77	11.53
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.01	-1.01	-1.02	-1.05	-1.11	-1.04	-1.00	-0.94	-0.88	-0.86
Leverage Ratio	1.03	1.03	1.04	1.07	1.19	1.14	1.12	1.16	1.19	1.20
Compound Leverage Factor	1.02	1.00	1.00	1.03	1.14	1.12	1.12	1.13	1.04	0.77
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	176.54	28.28	27.04	6.84	15.20	23.53	31.29	27.94	27.92	23.77
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	77.15	36.86	33.02	9.79	6.36	18.75	8.76	8.87	5.41	6.36
Quick Ratio	75.87	36.48	32.68	9.57	6.18	18.13	8.11	8.01	4.95	5.68
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-84	-73	-71	-94	-109	-189	-206	-243	-141	-136
Operating Cash Flow to CapEx	-11,884.80%	-186,376.17%	-11,126.43%	-30,201.58%	-18,273.01%	-86,169.66%	-79,859.69%	-34,728.28%	-46,170.63%	-22,725.78%
Free Cash Flow to Firm to Interest Expense	0.00	-1,988.54	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	-2,481.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	-2,482.43	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.05	0.14	0.40	0.63	0.65
Accounts Receivable Turnover	2.22	5.29	0.00	0.00	0.00	0.00	5.42	5.25	4.91	4.85
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	1.07	1.28	1.90	3.00
Fixed Asset Turnover	0.22	0.47	0.28	0.00	0.04	10.72	44.23	135.16	260.37	436.16
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.29	1.13	2.14	3.09	3.04
Days Sales Outstanding (DSO)	164.32	68.98	0.00	0.00	0.00	0.00	67.34	69.51	74.36	75.19
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	340.80	284.49	192.35	121.52
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	1,244.93	322.36	170.39	118.15	120.23
Cash Conversion Cycle (CCC)	164.32	68.98	0.00	0.00	0.00	-1,244.93	85.77	183.62	148.56	76.49
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	1.04	-8.60	-9.89	-30	-29	-1.99	4.16	62	92	146
Invested Capital Turnover	-0.02	-0.09	-0.03	0.00	0.00	-1.47	77.27	7.52	6.03	5.74
Increase / (Decrease) in Invested Capital	10	-9.64	-1.30	-20	0.81	27	6.14	58	29	54
Enterprise Value (EV)	1,839	269	326	276	1,672	1,890	3,850	4,418	6,393	7,852
Market Capitalization	2,314	653	790	623	1,896	2,549	4,264	5,012	6,893	8,855
Book Value per Share	$11.07	$8.68	$8.33	$5.81	$3.53	$8.19	$5.13	$6.93	$6.15	$10.83
Tangible Book Value per Share	$11.07	$8.68	$8.33	$5.81	$3.53	$8.19	$5.13	$6.93	$6.15	$10.83
Total Capital	476	376	454	318	195	657	418	656	591	1,148
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-475	-384	-464	-348	-224	-659	-414	-594	-500	-1,003
Capital Expenditures (CapEx)	0.86	0.05	0.72	0.39	0.70	0.27	0.33	0.78	0.27	0.32
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1.79	-6.43	-9.33	-28	-30	-4.80	0.19	61	45	99
Debt-free Net Working Capital (DFNWC)	477	378	455	319	194	654	414	655	544	1,102
Net Working Capital (NWC)	477	378	455	319	194	654	414	655	544	1,102
Net Nonoperating Expense (NNE)	31	34	26	42	40	65	84	72	28	-7.03
Net Nonoperating Obligations (NNO)	-475	-384	-464	-348	-224	-659	-414	-594	-500	-1,003
Total Depreciation and Amortization (D&A)	0.85	0.74	0.64	-0.57	-0.65	-0.12	-3.55	1.10	-7.87	-8.52
Debt-free, Cash-free Net Working Capital to Revenue	1,961.71%	-1,945.23%	-3,793.29%	0.00%	-49,346.24%	-21.03%	0.23%	24.40%	9.60%	14.52%
Debt-free Net Working Capital to Revenue	522,079.40%	114,201.84%	185,084.31%	0.00%	320,228.25%	2,867.01%	493.93%	261.56%	117.20%	161.81%
Net Working Capital to Revenue	522,079.40%	114,201.84%	185,084.31%	0.00%	320,228.25%	2,867.01%	493.93%	261.56%	117.20%	161.81%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($2.91)	($2.69)	($2.12)	($2.84)	($2.68)	($3.23)	($3.50)	($2.72)	($1.46)	($0.72)
Adjusted Weighted Average Basic Shares Outstanding	43.21M	43.41M	54.68M	55.12M	66.13M	80.92M	93.59M	94.05M	95.88M	103.13M
Adjusted Diluted Earnings per Share	($2.91)	($2.69)	($2.12)	($2.84)	($2.68)	($3.23)	($3.50)	($2.72)	($1.46)	($0.72)
Adjusted Weighted Average Diluted Shares Outstanding	43.21M	43.41M	54.68M	55.12M	66.13M	80.92M	93.59M	94.05M	95.88M	103.13M
Adjusted Basic & Diluted Earnings per Share	($2.91)	($2.69)	($2.12)	($2.84)	($2.68)	($3.23)	($3.50)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	36.07M	43.24M	46.18M	54.71M	55.19M	70.36M	81.25M	95.28M	96.81M	106.33M
Normalized Net Operating Profit after Tax (NOPAT)	-74	-83	-72	-114	-108	-162	-200	-185	-112	-82
Normalized NOPAT Margin	-81,071.10%	-25,031.97%	-29,282.85%	0.00%	-177,863.32%	-709.51%	-238.63%	-73.72%	-24.03%	-12.00%
Pre Tax Income Margin	-114,696.75%	-34,883.55%	-40,203.17%	0.00%	-243,711.05%	-995.01%	-339.03%	-102.37%	-29.94%	-10.90%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-3,215.22	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	-2,250.65	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	-3,216.55	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	-2,251.98	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.72%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Intra-Cellular Therapies' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	223.64%	242.29%	172.33%	99.34%	75.56%	50.34%	52.00%	45.67%	39.00%	50.81%
EBITDA Growth	29.90%	46.78%	34.71%	42.11%	42.48%	20.83%	53.67%	39.89%	-27.67%	12.13%
EBIT Growth	28.06%	44.87%	33.40%	46.34%	46.59%	28.08%	56.70%	41.24%	-30.75%	14.37%
NOPAT Growth	28.06%	44.87%	33.40%	46.34%	46.59%	28.08%	56.70%	41.24%	-30.75%	14.37%
Net Income Growth	30.43%	48.65%	38.92%	50.60%	54.66%	35.09%	65.39%	62.09%	-8.52%	40.92%
EPS Growth	40.00%	57.14%	41.03%	51.09%	56.14%	33.33%	65.22%	64.44%	0.00%	50.00%
Operating Cash Flow Growth	32.69%	46.45%	27.50%	61.18%	52.63%	94.74%	43.20%	101.47%	-4.97%	-534.55%
Free Cash Flow Firm Growth	-12.67%	-37.83%	-41.83%	22.92%	16.34%	41.84%	51.11%	43.21%	19.48%	-39.79%
Invested Capital Growth	580.49%	1,401.44%	346.89%	115.24%	92.81%	46.97%	40.13%	29.70%	28.90%	58.77%
Revenue Q/Q Growth	29.31%	22.26%	8.46%	16.25%	13.88%	4.70%	9.66%	11.41%	8.67%	13.60%
EBITDA Q/Q Growth	34.73%	16.52%	-8.44%	2.01%	35.15%	-14.89%	36.54%	-27.13%	-37.73%	20.92%
EBIT Q/Q Growth	36.73%	14.77%	-2.07%	2.51%	37.02%	-14.75%	38.55%	-32.32%	-40.13%	24.84%
NOPAT Q/Q Growth	36.73%	14.77%	-2.07%	2.51%	37.02%	-14.75%	38.55%	-32.32%	-40.13%	24.84%
Net Income Q/Q Growth	38.21%	17.72%	-0.06%	2.88%	43.30%	-17.81%	46.65%	-6.38%	-62.29%	35.86%
EPS Q/Q Growth	38.04%	21.05%	-2.22%	2.17%	44.44%	-20.00%	46.67%	0.00%	-56.25%	40.00%
Operating Cash Flow Q/Q Growth	43.72%	26.54%	-53.26%	38.73%	31.34%	91.84%	-1,555.31%	101.59%	-4,993.91%	50.70%
Free Cash Flow Firm Q/Q Growth	19.88%	-6.58%	-11.02%	18.70%	13.04%	25.90%	6.67%	5.57%	-23.30%	-28.64%
Invested Capital Q/Q Growth	27.84%	13.62%	39.63%	6.12%	14.51%	-13.39%	33.13%	-1.78%	13.80%	6.69%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	91.86%	92.27%	92.92%	93.53%	92.76%	91.90%	93.17%	92.96%	91.27%	89.76%
EBITDA Margin	-76.85%	-52.47%	-52.46%	-44.22%	-25.18%	-27.63%	-15.99%	-18.25%	-23.13%	-16.10%
Operating Margin	-77.40%	-53.96%	-50.78%	-42.58%	-23.55%	-25.81%	-14.46%	-17.18%	-22.15%	-14.66%
EBIT Margin	-77.40%	-53.96%	-50.78%	-42.58%	-23.55%	-25.81%	-14.46%	-17.18%	-22.15%	-14.66%
Profit (Net Income) Margin	-74.45%	-50.10%	-46.22%	-38.62%	-19.23%	-21.63%	-10.52%	-10.05%	-15.01%	-8.48%
Tax Burden Percent	100.00%	100.00%	100.02%	100.32%	100.18%	101.59%	102.41%	100.35%	101.44%	98.16%
Interest Burden Percent	96.19%	92.86%	91.01%	90.40%	81.50%	82.50%	71.06%	58.30%	66.80%	58.92%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-323.55%	-284.04%	-207.03%	-161.01%	-86.12%	-108.86%	-49.72%	-63.91%	-78.51%	-58.85%
ROIC Less NNEP Spread (ROIC-NNEP)	-320.93%	-281.88%	-205.48%	-159.38%	-85.51%	-108.00%	-49.61%	-64.32%	-78.63%	-59.32%
Return on Net Nonoperating Assets (RNNOA)	303.68%	264.41%	190.05%	143.14%	74.81%	94.65%	41.15%	56.52%	67.71%	51.23%
Return on Equity (ROE)	-19.88%	-19.62%	-16.98%	-17.88%	-11.31%	-14.21%	-8.57%	-7.39%	-10.80%	-7.62%
Cash Return on Invested Capital (CROIC)	-820.31%	-729.42%	-441.05%	-278.39%	-213.71%	-182.79%	-121.69%	-99.99%	-95.48%	-114.26%
Operating Return on Assets (OROA)	-21.75%	-21.70%	-19.83%	-20.42%	-13.20%	-16.16%	-10.12%	-9.53%	-13.31%	-9.52%
Return on Assets (ROA)	-20.92%	-20.15%	-18.05%	-18.52%	-10.77%	-13.55%	-7.36%	-5.58%	-9.02%	-5.51%
Return on Common Equity (ROCE)	-19.88%	-19.62%	-16.98%	-17.88%	-11.31%	-14.21%	-8.57%	-7.39%	-10.80%	-7.62%
Return on Equity Simple (ROE_SIMPLE)	-43.47%	0.00%	-36.36%	-30.37%	-25.82%	0.00%	-18.49%	-7.37%	-7.54%	0.00%
Net Operating Profit after Tax (NOPAT)	-39	-33	-34	-33	-21	-24	-15	-19	-27	-20
NOPAT Margin	-54.18%	-37.77%	-35.54%	-29.81%	-16.48%	-18.07%	-10.12%	-12.02%	-15.51%	-10.26%
Net Nonoperating Expense Percent (NNEP)	-2.63%	-2.15%	-1.55%	-1.63%	-0.61%	-0.86%	-0.11%	0.41%	0.12%	0.47%
Return On Investment Capital (ROIC_SIMPLE)	-	-5.06%	-	-	-	-4.04%	-	-	-	-1.78%
Cost of Revenue to Revenue	8.14%	7.73%	7.08%	6.47%	7.24%	8.10%	6.83%	7.04%	8.73%	10.24%
SG&A Expenses to Revenue	122.97%	107.70%	103.80%	91.17%	83.38%	79.27%	78.06%	75.33%	75.32%	69.13%
R&D to Revenue	46.30%	38.54%	39.90%	44.94%	32.93%	38.44%	29.57%	34.81%	38.10%	35.28%
Operating Expenses to Revenue	177.40%	139.57%	143.69%	136.12%	116.31%	117.71%	107.63%	110.14%	113.43%	104.41%
Earnings before Interest and Taxes (EBIT)	-56	-47	-48	-47	-30	-34	-21	-28	-39	-29
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-55	-46	-50	-49	-32	-37	-23	-29	-41	-32
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.41	7.64	8.22	10.01	8.33	11.65	11.11	6.32	6.75	7.71
Price to Tangible Book Value (P/TBV)	6.41	7.64	8.22	10.01	8.33	11.65	11.11	6.32	6.75	7.71
Price to Revenue (P/Rev)	23.35	20.02	16.61	16.60	11.91	14.84	12.96	12.81	12.60	13.01
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	68.49	70.79	53.00	60.11	42.59	69.69	50.62	51.74	49.25	53.91
Enterprise Value to Revenue (EV/Rev)	20.00	17.65	14.87	15.20	10.74	13.77	12.03	10.99	10.95	11.53
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.95	-0.94	-0.92	-0.90	-0.87	-0.88	-0.83	-0.88	-0.86	-0.86
Leverage Ratio	1.14	1.16	1.12	1.15	1.17	1.19	1.20	1.16	1.17	1.20
Compound Leverage Factor	1.10	1.08	1.02	1.04	0.95	0.98	0.85	0.68	0.78	0.71
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	25.78	28.89	31.04	32.46	24.02	28.49	25.51	24.28	25.42	23.98
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	9.81	8.87	8.87	7.58	6.81	5.41	5.12	7.81	7.66	6.36
Quick Ratio	8.92	8.01	7.79	6.61	5.78	4.95	4.50	7.22	6.94	5.68
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-86	-91	-102	-83	-72	-53	-50	-47	-58	-74
Operating Cash Flow to CapEx	-45,599.15%	0.00%	0.00%	0.00%	-9,429.10%	-206,100.00%	0.00%	0.00%	-3,811.06%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.28	0.40	0.39	0.48	0.56	0.63	0.70	0.56	0.60	0.65
Accounts Receivable Turnover	4.79	5.25	5.43	5.12	5.12	4.91	4.83	4.67	4.94	4.85
Inventory Turnover	1.02	1.28	1.33	0.79	0.90	1.90	1.67	1.33	1.42	3.00
Fixed Asset Turnover	93.58	135.16	156.72	192.90	216.96	260.37	311.38	364.09	323.53	436.16
Accounts Payable Turnover	1.23	2.14	2.39	2.87	2.40	3.09	3.69	3.25	4.51	3.04
Days Sales Outstanding (DSO)	76.13	69.51	67.20	71.31	71.33	74.36	75.53	78.13	73.83	75.19
Days Inventory Outstanding (DIO)	357.97	284.49	275.08	459.94	407.34	192.35	219.09	275.30	256.89	121.52
Days Payable Outstanding (DPO)	295.82	170.39	152.52	127.03	151.92	118.15	98.80	112.30	80.90	120.23
Cash Conversion Cycle (CCC)	138.27	183.62	189.76	404.22	326.75	148.56	195.82	241.13	249.82	76.49
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	55	62	87	92	106	92	122	120	137	146
Invested Capital Turnover	5.97	7.52	5.82	5.40	5.22	6.03	4.91	5.31	5.06	5.74
Increase / (Decrease) in Invested Capital	47	58	68	50	51	29	35	27	31	54
Enterprise Value (EV)	3,762	4,418	4,619	5,559	4,511	6,393	6,182	6,206	6,723	7,852
Market Capitalization	4,393	5,012	5,159	6,074	5,005	6,893	6,660	7,231	7,732	8,855
Book Value per Share	$7.26	$6.93	$6.59	$6.33	$6.25	$6.15	$6.19	$10.84	$10.83	$10.83
Tangible Book Value per Share	$7.26	$6.93	$6.59	$6.33	$6.25	$6.15	$6.19	$10.84	$10.83	$10.83
Total Capital	685	656	628	607	601	591	599	1,145	1,145	1,148
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-630	-594	-540	-515	-495	-500	-477	-1,025	-1,008	-1,003
Capital Expenditures (CapEx)	0.12	-0.03	0.00	0.00	0.27	0.00	0.00	0.00	0.70	-0.43
Debt-free, Cash-free Net Working Capital (DFCFNWC)	52	61	86	91	105	45	78	78	97	99
Debt-free Net Working Capital (DFNWC)	682	655	627	606	599	544	556	1,102	1,106	1,102
Net Working Capital (NWC)	682	655	627	606	599	544	556	1,102	1,106	1,102
Net Nonoperating Expense (NNE)	15	11	10	9.76	3.46	4.71	0.58	-3.19	-0.87	-3.55
Net Nonoperating Obligations (NNO)	-630	-594	-540	-515	-495	-500	-477	-1,025	-1,008	-1,003
Total Depreciation and Amortization (D&A)	0.40	1.31	-1.60	-1.81	-2.06	-2.40	-2.21	-1.72	-1.71	-2.88
Debt-free, Cash-free Net Working Capital to Revenue	27.57%	24.40%	27.70%	24.98%	24.89%	9.60%	15.25%	13.78%	15.85%	14.52%
Debt-free Net Working Capital to Revenue	362.73%	261.56%	201.69%	165.65%	142.65%	117.20%	108.13%	195.29%	180.15%	161.81%
Net Working Capital to Revenue	362.73%	261.56%	201.69%	165.65%	142.65%	117.20%	108.13%	195.29%	180.15%	161.81%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.57)	($0.45)	($0.46)	($0.45)	($0.25)	($0.30)	($0.16)	($0.16)	($0.25)	($0.15)
Adjusted Weighted Average Basic Shares Outstanding	94.52M	94.05M	95.13M	95.95M	96.14M	95.88M	96.88M	103.72M	105.77M	103.13M
Adjusted Diluted Earnings per Share	($0.57)	($0.45)	($0.46)	($0.45)	($0.25)	($0.30)	($0.16)	($0.16)	($0.25)	($0.15)
Adjusted Weighted Average Diluted Shares Outstanding	94.52M	94.05M	95.13M	95.95M	96.14M	95.88M	96.88M	103.72M	105.77M	103.13M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	94.71M	95.28M	95.93M	96.09M	96.24M	96.81M	105.57M	105.67M	106.02M	106.33M
Normalized Net Operating Profit after Tax (NOPAT)	-39	-33	-34	-33	-21	-24	-15	-19	-27	-20
Normalized NOPAT Margin	-54.18%	-37.77%	-35.54%	-29.81%	-16.48%	-18.07%	-10.12%	-12.02%	-15.51%	-10.26%
Pre Tax Income Margin	-74.45%	-50.10%	-46.21%	-38.49%	-19.19%	-21.30%	-10.28%	-10.02%	-14.80%	-8.63%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Intra-Cellular Therapies' Financials

When does Intra-Cellular Therapies's fiscal year end?

According to the most recent income statement we have on file, Intra-Cellular Therapies' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Intra-Cellular Therapies' net income changed over the last 9 years?

Intra-Cellular Therapies' net income appears to be on an upward trend, with a most recent value of -$74.68 million in 2024, falling from -$104.79 million in 2015. The previous period was -$139.67 million in 2023.

What is Intra-Cellular Therapies's operating income?

Intra-Cellular Therapies's total operating income in 2024 was -$116.72 million, based on the following breakdown:

Total Gross Profit: $623.89 million
Total Operating Expenses: $740.61 million

How has Intra-Cellular Therapies revenue changed over the last 9 years?

Over the last 9 years, Intra-Cellular Therapies' total revenue changed from $91.36 thousand in 2015 to $680.85 million in 2024, a change of 745,108.2%.

How much debt does Intra-Cellular Therapies have?

Intra-Cellular Therapies' total liabilities were at $218.45 million at the end of 2024, a 59.6% increase from 2023, and a 2,679.1% increase since 2015.

How much cash does Intra-Cellular Therapies have?

In the past 9 years, Intra-Cellular Therapies' cash and equivalents has ranged from $37.79 million in 2017 to $306.95 million in 2024, and is currently $306.95 million as of their latest financial filing in 2024.

How has Intra-Cellular Therapies' book value per share changed over the last 9 years?

Over the last 9 years, Intra-Cellular Therapies' book value per share changed from 11.07 in 2015 to 10.83 in 2024, a change of -2.1%.

Remove Ads

Related Companies

This page (NASDAQ:ITCI) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intra-Cellular Therapies (ITCI) Financials

Frequently Asked Questions About Intra-Cellular Therapies' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Intra-Cellular Therapies (ITCI) Financials

Annual Income Statements for Intra-Cellular Therapies

Quarterly Income Statements for Intra-Cellular Therapies

Annual Cash Flow Statements for Intra-Cellular Therapies

Quarterly Cash Flow Statements for Intra-Cellular Therapies

Annual Balance Sheets for Intra-Cellular Therapies

Quarterly Balance Sheets for Intra-Cellular Therapies

Annual Metrics and Ratios for Intra-Cellular Therapies

Quarterly Metrics and Ratios for Intra-Cellular Therapies

Frequently Asked Questions About Intra-Cellular Therapies' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools